Fig. 1From: Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational statusAlgorithm for the treatment of patients with recurrent platinum-sensitive, epithelial ovarian cancer and m-BRCA. PARP-I, PARP inhibitor; PLD, pegylated liposomal doxorubicinBack to article page